# Efficacy and Safety of Tocilizumab for TAO

> **NCT06087731** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Tocilizumab
- Thyroid Associated Ophthalmopathy

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT06087731
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-23
- **Primary completion:** 2023-09-23
- **Final completion:** 2023-09-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** For some personal reasons.
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087731, "Efficacy and Safety of Tocilizumab for TAO". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06087731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*